Shingles Vaccine Affordability and Its Impact on Public Health in South Africa

Shingles vaccine affordability remains a pressing concern as the recombinant zoster vaccine launches in South Africa. This vaccine delivers substantially higher efficacy and longer protection against herpes zoster and post-herpetic neuralgia than the live attenuated version withdrawn in 2024, yet its cost restricts access within the nation’s divided public-private health system.

Clinical Superiority and Regulatory Milestones

Approval by the South African Health Products Regulatory Authority relied on the vaccine’s non-live adjuvanted recombinant technology suitable for adults 50 years and older as well as immunocompromised individuals aged 18 and above. The two-dose schedule spaced two to six months apart establishes both its clinical foundation and the logistical demands for effective deployment.

Private Market Pricing and Access Gaps

Listed at R2,783 per dose inclusive of VAT, the full course from GSK costs over R5,500, representing progress from the R15,600 Section 21 import price but remaining substantially higher than the prior vaccine’s R2,300. Such pricing illustrates persistent shingles vaccine affordability challenges, with private schemes providing only partial coverage and public-sector inclusion facing intense budgetary competition.

Pathways Toward Broader Immunization Equity

Health Technology Assessment and value-based pricing will prove critical in determining if demonstrated reductions in incidence, hospitalization, and chronic pain can support reimbursement and address shingles vaccine affordability. Stakeholder proposals for tiered pricing, public-private partnerships, and locally generated HEOR evidence offer potential solutions to align the vaccine’s clinical value with improved access across all population segments, enhancing overall shingles vaccine affordability.

Bibliography

1. Spotlight NSP. “New shingles vaccine to be launched in SA private sector, but affordability may limit access.” June 25, 2026. https://www.spotlightnsp.co.za/2026/06/25/new-shingles-vaccine-to-be-launched-in-sa-private-sector-but-affordability-may-limit-access/
2. AllAfrica / Spotlight. “South Africa: New Shingles Vaccine to Be Launched in SA Private Sector…” June 25, 2026. https://allafrica.com/stories/202606250574.html
3. Healthcare MEA. “GSK launches Shingrix in South Africa following SAHPRA registration.” June 28, 2026. https://www.healthcaremea.com/2026/06/28/gsk-launches-shingrix-in-south-africa-following-sahpra-registration/
4. Business Day. “Effective shingles vaccine will be out of reach for the poor.” May 18, 2026. https://www.businessday.co.za/lifestyle/wellness/2026-05-18-effective-shingles-vaccine-will-be-out-of-reach-for-the-poor/
5. Daily Maverick / Spotlight. “Why most people in SA can’t get the shingles vaccine.” May 30, 2025 (updated context). https://www.dailymaverick.co.za/article/2025-05-30-why-most-people-in-sa-cant-get-the-shingles-vaccine/